Summary
Sangamo BioSciences, Inc. (Sangamo) is a clinical stage biopharmaceutical company. It undertakes the research and development (R&D) of novel DNA-binding proteins for therapeutic gene regulation and genome editing. The company carries out research, development and commercialization of a naturally occurring class of proteins zinc finger DNA-binding proteins (ZFPs), which act as a transcription factors for gene regulation and gene modification. ZFP Therapeutics has the potential to apply in the development of novel human therapeutics.
Sangamo BioSciences, Inc. Key Recent Developments
Feb 06, 2013: Sangamo Reports Revenue Of $8.9m In Q4 2012
Dec 10, 2012: Sangamo Biosciences Presents Data Demonstrating In Vivo Protein Replacement Platform At American Society Of Hematology Meeting
Dec 07, 2012: Sangamo BioSciences Provides Comprehensive Overview Of ZFP Therapeutic Development Programs At 2012 Analyst Briefing
Oct 24, 2012: Sangamo Reports Revenue Of $4.9m In Q3 2012
Jul 25, 2012: Sangamo Reports Total Revenue Of $4.6m In Q2 2012GDPH7227FSA
This comprehensive SWOT profile of Sangamo BioSciences, Inc. provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Sangamo BioSciences, Inc. (Sangamo) is a clinical stage biopharmaceutical company. It undertakes the research and development (R&D) of novel DNA-binding proteins for therapeutic gene regulation and genome editing. The company carries out research, development and commercialization of a naturally occurring class of proteins zinc finger DNA-binding proteins (ZFPs), which act as a transcription factors for gene regulation and gene modification. ZFP Therapeutics has the potential to apply in the development of novel human therapeutics.
Sangamo BioSciences, Inc. Key Recent Developments
Feb 06, 2013: Sangamo Reports Revenue Of $8.9m In Q4 2012
Dec 10, 2012: Sangamo Biosciences Presents Data Demonstrating In Vivo Protein Replacement Platform At American Society Of Hematology Meeting
Dec 07, 2012: Sangamo BioSciences Provides Comprehensive Overview Of ZFP Therapeutic Development Programs At 2012 Analyst Briefing
Oct 24, 2012: Sangamo Reports Revenue Of $4.9m In Q3 2012
Jul 25, 2012: Sangamo Reports Total Revenue Of $4.6m In Q2 2012GDPH7227FSA
This comprehensive SWOT profile of Sangamo BioSciences, Inc. provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
SECTION 1 - ABOUT THE COMPANY
Sangamo BioSciences, Inc. - Key Facts
Sangamo BioSciences, Inc. - Key Employees
Sangamo BioSciences, Inc. - Key Employee Biographies
Sangamo BioSciences, Inc. - Major Products and Services
Sangamo BioSciences, Inc. - Pharmaceutical Pipeline Products Data
Sangamo BioSciences, Inc., Pipeline Products by Therapy Area
Sangamo BioSciences, Inc., Pipeline Products by Development Phase
Sangamo BioSciences, Inc. - History
Sangamo BioSciences, Inc. - Company Statement
Sangamo BioSciences, Inc. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
SECTION 2 – COMPANY ANALYSIS
Sangamo BioSciences, Inc. - Business Description
Sangamo BioSciences, Inc. - SWOT Analysis
SWOT Analysis - Overview
Sangamo BioSciences, Inc. - Strengths
Strength - Increasing Liquidity
Strength - Focused Research and Development Activities
Strength - Proprietary Technology
Sangamo BioSciences, Inc. - Weaknesses
Weakness - Discontinued Project
Weakness - Lack of Commercialized Products
Sangamo BioSciences, Inc. - Opportunities
Opportunity - Market Potential: HIV
Opportunity - Strategic Agreements
Opportunity - Robust Pipeline Products
Sangamo BioSciences, Inc. - Threats
Threat - Intense Competition
Threat - Uncertain R&D Outcomes
Threat - Tightening of FDA’s Regulatory Oversight
Sangamo BioSciences, Inc. - Key Competitors
SECTION 3 – COMPANY FINANCIAL RATIOS
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES
Sangamo BioSciences, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013
Sangamo BioSciences, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2007 to YTD 2013
Sangamo BioSciences, Inc., Recent Deals Summary
SECTION 5 – COMPANY’S RECENT DEVELOPMENTS
Sangamo BioSciences, Inc., Recent Developments
Feb 06, 2013: Sangamo Reports Revenue Of $8.9m In Q4 2012
Dec 10, 2012: Sangamo Biosciences Presents Data Demonstrating In Vivo Protein Replacement Platform At American Society Of Hematology Meeting
Dec 07, 2012: Sangamo BioSciences Provides Comprehensive Overview Of ZFP Therapeutic Development Programs At 2012 Analyst Briefing
Oct 24, 2012: Sangamo Reports Revenue Of $4.9m In Q3 2012
Jul 25, 2012: Sangamo Reports Total Revenue Of $4.6m In Q2 2012
Jul 03, 2012: Sangamo Provides Update On ZFP Therapeutic Development Programs At JMP Securities Healthcare Conference
May 02, 2012: Sangamo Reports Revenue Of $3.2m In Q1 2012
Apr 12, 2012: Sangamo Announces Presentation At Future Leaders In Biotech Industry Conference
Apr 02, 2012: Sangamo Announces Publication Of Study Demonstrating Use Of ZFN Technology To Develop Safer And Effective Cancer Treatments In Nature Medicine
Mar 28, 2012: Sangamo BioSciences Announces Presentation At Needham Healthcare Conference
SECTION 6 – APPENDIX
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
LIST OF TABLES
Sangamo BioSciences, Inc., Key Facts
Sangamo BioSciences, Inc., Key Employees
Sangamo BioSciences, Inc., Key Employee Biographies
Sangamo BioSciences, Inc., Major Products and Services
Sangamo BioSciences, Inc., Number of Pipeline Products by Therapy Area
Sangamo BioSciences, Inc., Number of Pipeline Products by Development Stage
Sangamo BioSciences, Inc., Pipeline Products By Therapy Area and Development Phase
Sangamo BioSciences, Inc., History
Sangamo BioSciences, Inc., Subsidiaries
Sangamo BioSciences, Inc., Key Competitors
Sangamo BioSciences, Inc., Ratios based on current share price
Sangamo BioSciences, Inc., Annual Ratios
Sangamo BioSciences, Inc., Interim Ratios
Sangamo BioSciences, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013
Sangamo BioSciences, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2007 to YTD 2013
Sangamo BioSciences, Inc., Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
LIST OF FIGURES
Sangamo BioSciences, Inc., Pipeline Products by Therapy Area
Sangamo BioSciences, Inc., Pipeline Products by Development Phase
Sangamo BioSciences, Inc., Performance Chart (2008 - 2012)
Sangamo BioSciences, Inc., Ratio Charts
Sangamo BioSciences, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013
Sangamo BioSciences, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2007 to YTD 2013
Sangamo BioSciences, Inc. - Key Facts
Sangamo BioSciences, Inc. - Key Employees
Sangamo BioSciences, Inc. - Key Employee Biographies
Sangamo BioSciences, Inc. - Major Products and Services
Sangamo BioSciences, Inc. - Pharmaceutical Pipeline Products Data
Sangamo BioSciences, Inc., Pipeline Products by Therapy Area
Sangamo BioSciences, Inc., Pipeline Products by Development Phase
Sangamo BioSciences, Inc. - History
Sangamo BioSciences, Inc. - Company Statement
Sangamo BioSciences, Inc. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
SECTION 2 – COMPANY ANALYSIS
Sangamo BioSciences, Inc. - Business Description
Sangamo BioSciences, Inc. - SWOT Analysis
SWOT Analysis - Overview
Sangamo BioSciences, Inc. - Strengths
Strength - Increasing Liquidity
Strength - Focused Research and Development Activities
Strength - Proprietary Technology
Sangamo BioSciences, Inc. - Weaknesses
Weakness - Discontinued Project
Weakness - Lack of Commercialized Products
Sangamo BioSciences, Inc. - Opportunities
Opportunity - Market Potential: HIV
Opportunity - Strategic Agreements
Opportunity - Robust Pipeline Products
Sangamo BioSciences, Inc. - Threats
Threat - Intense Competition
Threat - Uncertain R&D Outcomes
Threat - Tightening of FDA’s Regulatory Oversight
Sangamo BioSciences, Inc. - Key Competitors
SECTION 3 – COMPANY FINANCIAL RATIOS
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES
Sangamo BioSciences, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013
Sangamo BioSciences, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2007 to YTD 2013
Sangamo BioSciences, Inc., Recent Deals Summary
SECTION 5 – COMPANY’S RECENT DEVELOPMENTS
Sangamo BioSciences, Inc., Recent Developments
Feb 06, 2013: Sangamo Reports Revenue Of $8.9m In Q4 2012
Dec 10, 2012: Sangamo Biosciences Presents Data Demonstrating In Vivo Protein Replacement Platform At American Society Of Hematology Meeting
Dec 07, 2012: Sangamo BioSciences Provides Comprehensive Overview Of ZFP Therapeutic Development Programs At 2012 Analyst Briefing
Oct 24, 2012: Sangamo Reports Revenue Of $4.9m In Q3 2012
Jul 25, 2012: Sangamo Reports Total Revenue Of $4.6m In Q2 2012
Jul 03, 2012: Sangamo Provides Update On ZFP Therapeutic Development Programs At JMP Securities Healthcare Conference
May 02, 2012: Sangamo Reports Revenue Of $3.2m In Q1 2012
Apr 12, 2012: Sangamo Announces Presentation At Future Leaders In Biotech Industry Conference
Apr 02, 2012: Sangamo Announces Publication Of Study Demonstrating Use Of ZFN Technology To Develop Safer And Effective Cancer Treatments In Nature Medicine
Mar 28, 2012: Sangamo BioSciences Announces Presentation At Needham Healthcare Conference
SECTION 6 – APPENDIX
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
LIST OF TABLES
Sangamo BioSciences, Inc., Key Facts
Sangamo BioSciences, Inc., Key Employees
Sangamo BioSciences, Inc., Key Employee Biographies
Sangamo BioSciences, Inc., Major Products and Services
Sangamo BioSciences, Inc., Number of Pipeline Products by Therapy Area
Sangamo BioSciences, Inc., Number of Pipeline Products by Development Stage
Sangamo BioSciences, Inc., Pipeline Products By Therapy Area and Development Phase
Sangamo BioSciences, Inc., History
Sangamo BioSciences, Inc., Subsidiaries
Sangamo BioSciences, Inc., Key Competitors
Sangamo BioSciences, Inc., Ratios based on current share price
Sangamo BioSciences, Inc., Annual Ratios
Sangamo BioSciences, Inc., Interim Ratios
Sangamo BioSciences, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013
Sangamo BioSciences, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2007 to YTD 2013
Sangamo BioSciences, Inc., Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
LIST OF FIGURES
Sangamo BioSciences, Inc., Pipeline Products by Therapy Area
Sangamo BioSciences, Inc., Pipeline Products by Development Phase
Sangamo BioSciences, Inc., Performance Chart (2008 - 2012)
Sangamo BioSciences, Inc., Ratio Charts
Sangamo BioSciences, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013
Sangamo BioSciences, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2007 to YTD 2013
